Canada has become the first G7 nation to approve a generic version of semaglutide, the blockbuster diabetes and weight-loss drug, in a move that promises to slash costs for patients by up to 90 per cent. Health Canada’s decision, which authorises a product manufactured by Dr Reddy’s Laboratories in India, arrives amid a global re-evaluation of how these therapies are understood and managed. Viewed from Ottawa, the approval is a pragmatic response to soaring demand and the financial burden on uninsured patients, but it also opens a new front in the ongoing debate about the long-term tolerability of such treatments.

Researchers are now probing the mechanisms behind the most common side effects of GLP-1 drugs, notably the nausea and gastrointestinal distress that lead many patients to abandon therapy. Scientists in Buenos Aires report having identified what they call a “master key” in the enteric nervous system — the so-called second brain — that could modulate these adverse reactions, potentially improving patient adherence. Separately, clinicians note that the drugs have a profound psychological effect, silencing what patients describe as relentless “food noise” — the constant internal dialogue about eating. This shift in perception is prompting a broader inquiry into how metabolic interventions alter behaviour beyond mere appetite suppression.

The same week, new evidence from Australia’s Monash University has linked ultra-processed foods to diminished cognitive function. Researchers found that a daily increase of just ten per cent in consumption of such foods — equivalent to a single bag of crisps — correlates with lower attention scores and higher dementia risk, even when the overall diet appears otherwise healthy. A Russian geriatrician, commenting on parallel studies, noted that fourteen modifiable risk factors, including diet, exercise, and social isolation, can nearly halve the likelihood of developing dementia. These findings reinforce a growing consensus that what we eat does not merely shape our waistlines but also the long-term health of our brains.

Yet not all dietary habits are detrimental. A separate study published in the Journal of Affective Disorders suggests that moderate coffee consumption may reduce the risk of stress-related mood disorders. The key, researchers in Argentina argue, lies in finding the precise dosage that transforms a daily ritual from a potential trigger of anxiety into a protective ally. Such nuance is characteristic of a moment in metabolic medicine where single interventions — whether a generic drug, a cup of coffee, or a bag of crisps — are part of a far more intricate web of cause and effect. Looking ahead, the challenge for policymakers and clinicians will be to integrate these insights: ensuring affordable access to effective therapies while simultaneously addressing the lifestyle factors that underpin both metabolic and cognitive health at a population level.